(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






2 Result: NYSE:AMPX

Buy-Rated: AMPX, RIVN, FDMT, CBAY, HTZ, PED - Unlocking Upside Potential

July 05th, 2023

Amprius Technologies, Inc. (NYSE: AMPX), a leading provider of advanced lithium-ion battery technology, was assumed by EF Hutton with a Buy rating and a price target of $14. With $AMPX closing at $6.98 on Monday, the assigned price target suggests. Read more

NewAmsterdam, Acrivon, Veeva Systems, Amprius Technologies: Latest Updates, Potential Upsides

June 04th, 2023

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) released the comprehensive findings from the ROSE2 Phase 2 clinical trial, which examined the efficacy of obicetrapib, their oral, low-dose cholesteryl ester transfer protein inhibitor, in conjunction w. Read more

Load More Content